Literature DB >> 20185911

Effects of iron deprivation on multidrug resistance of leukemic K562 cells.

Dingzhu Fang1, Yixiao Bao, Xiaobin Li, Fang Liu, Kang Cai, Ju Gao, Qingkui Liao.   

Abstract

BACKGROUND AND AIM: Multidrug resistance (MDR) compromises the efficacy of chemotherapy. Many approaches have been used to reduce MDR; however, the results are poor. It has been reported that iron deprivation downregulates MDR genes. To investigate the relationship of iron with MDR and early growth response gene-1 (EGR1), we investigated the effect of iron deprivation on expression and/or function of multidrug resistance-1 (MDR1), early growth response gene-1 (EGR1), ferritin heavy chain gene (H-Fn) and MDR1-encoded P-glycoprotein (P-gp) in the K562 leukemic cell line.
METHODS: The cells were stimulated with 12-O-tetradecanoylphorbol-13-acetate (TPA) and incubated with either FeCl(3) or the iron-chelating drug DFO. The mRNA levels of MDR1, EGR1 and H-Fn were detected by RT-PCR. The protein expression and function of P-gp were measured by immunohistochemical staining and flow cytometry, respectively.
RESULTS: DFO significantly reduced the intracellular iron level, and led to approximately 70% reduction of MDR1 mRNA, approximately 50% of reduction of H-Fn mRNA and approximately 30% reduction of P-gp protein in TPA-differentiated K562 cells. The P-gp pump function, measured by daunorubicin exclusion, was also reduced by DFO treatment.
CONCLUSIONS: These results suggest a close relationship between iron deprivation and reduced MDR1/P-gp expression and function. DFO may be used together with chemotherapeutic drugs to achieve better clinical efficacy. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185911     DOI: 10.1159/000287352

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

1.  Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.

Authors:  R D Spagnuolo; S Recalcati; L Tacchini; G Cairo
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

2.  Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.

Authors:  S J Ford; P Obeidy; D B Lovejoy; M Bedford; L Nichols; C Chadwick; O Tucker; G Y L Lui; D S Kalinowski; P J Jansson; T H Iqbal; D Alderson; D R Richardson; C Tselepis
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

3.  The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels.

Authors:  Karolin Franke; Melanie Kettering; Kathleen Lange; Werner A Kaiser; Ingrid Hilger
Journal:  Int J Nanomedicine       Date:  2013-01-20

4.  Iron protects childhood acute lymphoblastic leukemia cells from methotrexate cytotoxicity.

Authors:  Marjan Abedi; Soheila Rahgozar; Abolghasem Esmaeili
Journal:  Cancer Med       Date:  2020-03-16       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.